vs
Side-by-side financial comparison of John Marshall Bancorp, Inc. (JMSB) and STRATA Skin Sciences, Inc. (SSKN). Click either name above to swap in a different company.
John Marshall Bancorp, Inc. is the larger business by last-quarter revenue ($16.8M vs $9.3M, roughly 1.8× STRATA Skin Sciences, Inc.). John Marshall Bancorp, Inc. runs the higher net margin — 36.3% vs 0.6%, a 35.7% gap on every dollar of revenue. Over the past eight quarters, STRATA Skin Sciences, Inc.'s revenue compounded faster (17.3% CAGR vs 15.3%).
John Marshall Bancorp, Inc. is a U.S.-based bank holding company that operates through its wholly owned subsidiary John Marshall Bank. It provides a full suite of commercial and consumer banking products including deposit accounts, commercial loans, residential mortgages, and personal financial services, primarily serving retail customers and small-to-mid-sized businesses across the U.S. Mid-Atlantic region.
Strata Skin Sciences is an American medical device company focused on the design, development and commercialization of non-invasive tools to provide additional information to dermatologists during melanoma skin examinations.
JMSB vs SSKN — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $16.8M | $9.3M |
| Net Profit | $6.1M | $58.0K |
| Gross Margin | — | 61.8% |
| Operating Margin | — | 5.3% |
| Net Margin | 36.3% | 0.6% |
| Revenue YoY | — | -3.0% |
| Net Profit YoY | 26.8% | 101.3% |
| EPS (diluted) | $0.43 | $0.14 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $16.8M | — | ||
| Q4 25 | $16.4M | $9.3M | ||
| Q3 25 | $16.3M | $6.9M | ||
| Q2 25 | $15.4M | $7.7M | ||
| Q1 25 | $14.6M | $6.8M | ||
| Q4 24 | $14.3M | $9.6M | ||
| Q3 24 | $13.8M | $8.8M | ||
| Q2 24 | $12.6M | $8.4M |
| Q1 26 | $6.1M | — | ||
| Q4 25 | $5.9M | $58.0K | ||
| Q3 25 | $5.4M | $-1.6M | ||
| Q2 25 | $5.1M | $-2.6M | ||
| Q1 25 | $4.8M | $-2.1M | ||
| Q4 24 | $4.8M | $-4.6M | ||
| Q3 24 | $4.2M | $-2.1M | ||
| Q2 24 | $3.9M | $-91.0K |
| Q1 26 | — | — | ||
| Q4 25 | — | 61.8% | ||
| Q3 25 | — | 60.4% | ||
| Q2 25 | — | 56.2% | ||
| Q1 25 | — | 53.5% | ||
| Q4 24 | — | 61.4% | ||
| Q3 24 | — | 60.1% | ||
| Q2 24 | — | 59.0% |
| Q1 26 | — | — | ||
| Q4 25 | 47.4% | 5.3% | ||
| Q3 25 | 42.2% | -16.9% | ||
| Q2 25 | 42.7% | -30.1% | ||
| Q1 25 | 42.4% | -25.0% | ||
| Q4 24 | 42.5% | -44.7% | ||
| Q3 24 | 38.8% | -18.2% | ||
| Q2 24 | 39.7% | -5.7% |
| Q1 26 | 36.3% | — | ||
| Q4 25 | 36.2% | 0.6% | ||
| Q3 25 | 33.2% | -23.4% | ||
| Q2 25 | 33.1% | -33.6% | ||
| Q1 25 | 32.9% | -31.2% | ||
| Q4 24 | 33.3% | -47.6% | ||
| Q3 24 | 30.7% | -23.6% | ||
| Q2 24 | 30.9% | -1.1% |
| Q1 26 | $0.43 | — | ||
| Q4 25 | $0.41 | $0.14 | ||
| Q3 25 | $0.38 | $-0.36 | ||
| Q2 25 | $0.36 | $-0.62 | ||
| Q1 25 | $0.34 | $-0.51 | ||
| Q4 24 | $0.33 | $-2.01 | ||
| Q3 24 | $0.30 | $-0.51 | ||
| Q2 24 | $0.27 | $-0.03 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $150.2M | $7.9M |
| Total DebtLower is stronger | — | $15.3M |
| Stockholders' EquityBook value | $268.1M | $2.9M |
| Total Assets | $2.4B | $30.5M |
| Debt / EquityLower = less leverage | — | 5.28× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $150.2M | — | ||
| Q4 25 | $130.0M | $7.9M | ||
| Q3 25 | $163.6M | $7.1M | ||
| Q2 25 | $116.9M | $6.0M | ||
| Q1 25 | $169.1M | $6.5M | ||
| Q4 24 | $122.5M | $7.3M | ||
| Q3 24 | $177.2M | $7.1M | ||
| Q2 24 | $182.6M | $5.5M |
| Q1 26 | — | — | ||
| Q4 25 | $80.9M | $15.3M | ||
| Q3 25 | $80.9M | $15.3M | ||
| Q2 25 | $80.8M | $15.0M | ||
| Q1 25 | $80.8M | $15.0M | ||
| Q4 24 | $80.8M | $15.0M | ||
| Q3 24 | $80.8M | $15.0M | ||
| Q2 24 | $24.7M | $15.0M |
| Q1 26 | $268.1M | — | ||
| Q4 25 | $265.6M | $2.9M | ||
| Q3 25 | $259.7M | $1.3M | ||
| Q2 25 | $253.7M | $532.0K | ||
| Q1 25 | $253.0M | $3.0M | ||
| Q4 24 | $246.6M | $5.0M | ||
| Q3 24 | $243.1M | $9.4M | ||
| Q2 24 | $235.3M | $9.5M |
| Q1 26 | $2.4B | — | ||
| Q4 25 | $2.3B | $30.5M | ||
| Q3 25 | $2.3B | $30.7M | ||
| Q2 25 | $2.3B | $29.5M | ||
| Q1 25 | $2.3B | $33.0M | ||
| Q4 24 | $2.2B | $34.9M | ||
| Q3 24 | $2.3B | $39.4M | ||
| Q2 24 | $2.3B | $38.8M |
| Q1 26 | — | — | ||
| Q4 25 | 0.30× | 5.28× | ||
| Q3 25 | 0.31× | 11.65× | ||
| Q2 25 | 0.32× | 28.20× | ||
| Q1 25 | 0.32× | 5.04× | ||
| Q4 24 | 0.33× | 3.02× | ||
| Q3 24 | 0.33× | 1.60× | ||
| Q2 24 | 0.11× | 1.58× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-239.0K |
| Free Cash FlowOCF − Capex | — | $-551.0K |
| FCF MarginFCF / Revenue | — | -5.9% |
| Capex IntensityCapex / Revenue | — | 3.4% |
| Cash ConversionOCF / Net Profit | — | -4.12× |
| TTM Free Cash FlowTrailing 4 quarters | — | $-4.4M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $22.6M | $-239.0K | ||
| Q3 25 | $1.2M | $-64.0K | ||
| Q2 25 | $7.5M | $-1.9M | ||
| Q1 25 | $7.0M | $-550.0K | ||
| Q4 24 | $17.3M | $703.0K | ||
| Q3 24 | $1.4M | $-302.0K | ||
| Q2 24 | $10.2M | $591.0K |
| Q1 26 | — | — | ||
| Q4 25 | $22.0M | $-551.0K | ||
| Q3 25 | $1.2M | $-1.1M | ||
| Q2 25 | $7.4M | $-2.0M | ||
| Q1 25 | $6.6M | $-749.0K | ||
| Q4 24 | $16.8M | $199.0K | ||
| Q3 24 | $1.3M | $-364.0K | ||
| Q2 24 | $10.1M | $246.0K |
| Q1 26 | — | — | ||
| Q4 25 | 134.7% | -5.9% | ||
| Q3 25 | 7.3% | -15.6% | ||
| Q2 25 | 47.8% | -26.1% | ||
| Q1 25 | 45.3% | -11.0% | ||
| Q4 24 | 116.9% | 2.1% | ||
| Q3 24 | 9.5% | -4.1% | ||
| Q2 24 | 80.1% | 2.9% |
| Q1 26 | — | — | ||
| Q4 25 | 3.4% | 3.4% | ||
| Q3 25 | 0.2% | 14.7% | ||
| Q2 25 | 1.0% | 0.8% | ||
| Q1 25 | 2.3% | 2.9% | ||
| Q4 24 | 3.4% | 5.3% | ||
| Q3 24 | 0.8% | 0.7% | ||
| Q2 24 | 0.4% | 4.1% |
| Q1 26 | — | — | ||
| Q4 25 | 3.82× | -4.12× | ||
| Q3 25 | 0.23× | — | ||
| Q2 25 | 1.48× | — | ||
| Q1 25 | 1.45× | — | ||
| Q4 24 | 3.61× | — | ||
| Q3 24 | 0.33× | — | ||
| Q2 24 | 2.60× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
JMSB
| Net Interest Income | $16.5M | 98% |
| Noninterest Income | $284.0K | 2% |
SSKN
| Dermatology Recurring Procedures | $6.1M | 65% |
| Dermatology Procedures Equipment | $3.2M | 35% |
